Galvanize Therapeutics closed an oversubscribed $130 million Series D to expand Aliya, advance RheOx, and build its next PEF platform.

Galvanize raises $130M Series D led by HealthQuest

Galvanize raises $130M Series D led by HealthQuest

Image: AI-generated editorial illustration

Galvanize Therapeutics said on November 16, 2026, that it closed an oversubscribed $130 million Series D led by HealthQuest Capital. The Redwood City medtech company plans to use the money to expand commercialization of Aliya, generate clinical evidence, advance RheOx, and develop a next-generation pulsed electric field platform.

Galvanize Therapeutics closed an oversubscribed $130 million Series D financing on November 16, 2026, giving the Redwood City medtech company fresh capital to expand commercialization and continue building out its pulsed electric field, or PEF, platform. HealthQuest Capital led the round, while Olympus Innovation Ventures and Braidwell LP joined as new investors, alongside existing backers including Sofinnova Partners, Norwest, Elevage Medical Technologies, Ally Bridge Group, Perceptive Advisors, Janus Henderson Investors, Longaeva Partners, Fidelity Management & Research Company, and T. Rowe Price Associates, Inc.

The company said the proceeds are intended to support Aliya commercial expansion, clinical evidence generation, RheOx advancement, and next-generation PEF platform development. Guided Solutions reported that the financing will also support Aliya, RheOx, and a next-generation platform effort, while Wilson Sonsini said the round was oversubscribed.

What did Galvanize raise and who backed it?

Galvanize raised a $130 million Series D, with HealthQuest Capital as lead investor. Wilson Sonsini, which advised the company on the transaction, said Olympus Innovation Ventures and Braidwell LP joined as new investors, and that a broad group of existing investors also participated.

Axios separately reported the same $130 million Series D and identified HealthQuest as the lead, with Olympus Innovation Ventures and Braidwell participating. The deal follows Galvanize’s oversubscribed $100 million Series C, which Hoodline said was announced in September 2025 and led by Sofinnova Partners.

HealthQuest founder and managing partner Garheng Kong will join Galvanize’s board as part of the transaction, according to Hoodline and Guided Solutions. Citybiz said HealthQuest manages approximately $2 billion in assets.

What does Galvanize do with Aliya and RheOx?

Galvanize is building products around PEF, a non-thermal ablation approach that uses short electrical pulses to disrupt cellular processes. Citybiz described Aliya as delivering high-voltage, short-duration electrical energy to induce regulated cell death in soft tissue without relying on thermal energy, while Hoodline said Aliya EX is the next-generation generator for the Aliya PEF System.

Guided Solutions reported that Aliya is 510(k)-cleared for surgical ablation of soft tissue. Hoodline said the company had also launched first commercial procedures using Aliya EX in August, including percutaneous and endoscopic delivery. Hoodline added that Aliya PEF is 510(k)-cleared in the United States for surgical ablation of soft tissue and is not currently commercially available in other geographies.

RheOx remains investigational in the United States and is limited to investigational use under federal law, according to Hoodline. The company’s plan, as described in the financing announcement and follow-on coverage, is to use the new capital to move RheOx forward while also broadening Aliya’s commercial footprint.

What operating milestones did Galvanize highlight?

Galvanize pointed to a mix of commercial, clinical, and publication milestones ahead of the financing. Guided Solutions said the company received FDA clearance and launched the Aliya EX Generator over the prior year, and that it had surpassed 4,000 procedures and enrolled more than 300 patients in its PROPEL registry.

Citybiz and Hoodline both reported company-provided figures showing more than 4,000 Aliya procedures and more than 300 patients enrolled in PROPEL by the time the financing was announced. Citybiz also said Galvanize reported more than 40 peer-reviewed publications on PEF mechanisms, outcomes, and applications, while Guided Solutions described more than 40 peer-reviewed publications on PEF.

Hoodline reported that Galvanize said preclinical and early clinical data suggest Aliya PEF may promote antigen release that could activate the immune system, but that benefit has not been established. That matters because it shows the company is still translating early data into evidence, rather than claiming a proven immune effect.

What happens next for the company?

The immediate next step is deploying the Series D proceeds across commercial, clinical, and platform-development work. Guided Solutions attributed a quote to CEO Doug Godshall calling the financing an important inflection point and saying the company aims to broaden PEF’s role across oncology and chronic disease.

Citybiz said Godshall was appointed CEO and chairman in 2025. Before joining Galvanize, he was president and CEO of Shockwave Medical, which Johnson & Johnson acquired in 2024 for $13.1 billion, and earlier led HeartWare before Medtronic acquired it in 2016 for $1.1 billion.

For Galvanize, the financing gives it more room to push Aliya commercialization, build clinical evidence around its PEF approach, and advance RheOx and the next-generation platform work the company has already outlined. The round also adds a board seat for HealthQuest’s Garheng Kong, extending the investor’s role beyond capital into governance.

Sources